论文部分内容阅读
目的通过对比乳腺癌原代培养细胞对吡柔比星和表柔比星的药物敏感性,来评估吡柔比星和表柔比星在乳腺癌中敏感性的差别,并进一步指导临床化疗药物的选择。方法收集天津医科大学附属肿瘤医院乳腺中心129例原发性乳腺癌患者的新鲜癌组织,采用胶原凝胶体包埋肿瘤细胞原代培养法培养原代乳腺癌细胞,检测其对吡柔比星和表柔比星的敏感性。结果乳腺癌细胞对吡柔比星和表柔比星的药物敏感性差异无显著性(P=0.743);乳腺癌细胞对吡柔比星和表柔比星的药物敏感性有一定的相关性(P=0.001),Spearm an相关系数为0.294。结论乳腺癌细胞对吡柔比星和表柔比星的药物敏感性无差异,且乳腺癌细胞对两组药物的敏感性有一定的相关性,吡柔比星可以与表柔比星一样作为乳腺癌的常规化疗药物。CD-DST方法可以作为指导临床选择蒽环类药物的有效方法。
Objective To evaluate the sensitivity of pirarubicin and epirubicin in breast cancer by comparing the drug sensitivity of primary breast cancer cells to pirarubicin and epirubicin and to further guide clinical chemotherapeutic drugs s Choice. Methods Fresh cancer tissues from 129 patients with primary breast cancer at the Tumor Hospital Affiliated Tumor Hospital of Tianjin Medical University were collected. Primary breast cancer cells were cultured by primary culture of tumor cells embedded in collagen gel, And epirubicin sensitivity. Results There was no significant difference in the drug sensitivity of breast cancer cells to pirarubicin and epirubicin (P = 0.743). The breast cancer cells had some correlation with the drug sensitivity of pirarubicin and epirubicin (P = 0.001), Spearm an correlation coefficient of 0.294. Conclusion There is no difference in the drug sensitivity of breast cancer cells to pirarubicin and epirubicin, and the breast cancer cells have some correlation with the sensitivity of the two groups of drugs. Pirarubicin can be the same as epirubicin Conventional chemotherapy drugs for breast cancer. CD-DST method can be used as an effective method to guide the clinical choice of anthracyclines.